Increased exposure to fondaparinux, as observed in patients with renal impairment, may increase bleeding risk. This study aims to determine the time course of major bleeding after major orthopaedic surgery, identify predictors of bleeding and simulate the effect of a reduced dose of fondaparinux on bleeding for patients with moderate renal impairment (creatinine clearance = 20-50 ml min À1 ).
Introduction
Fondaparinux is a synthetic, selective factor Xa inhibitor indicated for the prevention of venous thromboembolism (VTE) [1] . In major orthopaedic surgery, randomized control trials demonstrated that fondaparinux 2.5 mg by subcutaneous injection once a day was more effective than enoxaparin to reduce VTE [2] . However, this higher effectiveness was offset by a significant increase risk of major bleeding. This adverse event has a clinical impact as it raises medical costs, is a predictor of mortality and is considered as equivalent to symptomatic VTE in its disutility [1, 3, 4] .
Fondaparinux clearance decreases as renal function decreases [5] . Pharmacokinetic simulations indicated that a once-daily administration of 1.5 mg fondaparinux in patients with moderate renal impairment (creatinine clearance between 20 and 50 ml min À1 estimated by the Cockcroft-Gault equation using, as body size descriptor, body weight) resulted in a predicted exposure to the drug similar to that achieved with 2.5 mg in patients with normal renal function [5] . Thus, a reduced dose of 1.5 mg of fondaparinux was recommended for venous thromboprophylaxis in patients with moderate renal impairment [6] , but it is unknown whether this dose adjustment results in a reduction in major bleeding events. The relationship between fondaparinux plasma concentrations and bleeding events has never been identified. Risk factors for major bleeding associated with VTE prophylaxis in orthopaedic surgery are not well defined and little is known about the associated time course of haemorrhagic events after surgery. Further, it is uncertain whether the rates of bleeding events observed in the randomized studies with highly selected patient cohorts reflect the real-world setting. The POPulation at RIsk with fondaparinuX thrombophylaxis study (POP-A-RIX) [7] and the PRophylaxis in Orthopedic surgery in Patients with renal Insufficiency as defined by a Creatinine clearancE between 20 and 50 ml min -1 study (PROPICE) [8, 9] were two prospective open label cohort studies that included patients undergoing major orthopaedic surgery in everyday practice. The first cohort included patients treated with fondaparinux 2.5 mg once daily, and the second included patients with renal impairment treated with an adjusted dose of fondaparinux 1.5 mg once a day. We used data from these studies to: (i) determine the time course of the risk of major bleeding after major orthopaedic surgery; (ii) identify clinical and biological predictors of bleeding, in particular the contribution of fondaparinux anti-Xa activity; and (iii) simulate the effect of a reduced dose of fondaparinux 1.5 mg once a day on bleeding for patients with moderate renal impairment.
Methods

Study design
The design and pharmacokinetic results of the POP-A-RIX and PROPICE studies were presented previously [7, 9] . Both studies were a multicentre, prospective, noncompara 
Patients and treatment
In both studies, consecutive patients aged >18 years, scheduled for major orthopaedic surgery were eligible for inclusion. Major orthopaedic surgery was defined as hip fracture surgery, primary or revision hip arthroplasty, and primary or revision knee arthroplasty.
At the time of the completion of POP-A-RIX (September 2004 to February 2007), a dose adjustment of fondaparinux in renal impaired patients was not recommended. Patients with a creatinine clearance above 30 ml min -1 were administered fondaparinux 2.5 mg subcutaneously once a day. The PROPICE study started in June 2007 and was completed in October 2008. Eligible patients had to present a creatinine clearance between 20 and 50 ml min -1 according to the Cockcroft-Gault formula [10] , and were treated with fondaparinux 1.5 mg subcutaneously once a day. Exclusion criteria included a contraindication to the use of fondaparinux and requirement for continued anticoagulant therapy [6] . The first dose of fondaparinux was administered at least 6 h postoperatively, the second dose being given 12 hours or more after the first. The recommended duration of venous thromboprophylaxis was 5 weeks [1] . For this pharmacodynamic analysis, we excluded 25 patients from the POP-A-RIX study who did not have major orthopaedic surgery and 23 patients (17 from POP-A-RIX and six from PROPICE) who received the first dose of fondaparinux >24 h after the end of surgery because the study drug was not administered as recommended [1] . None of these excluded patients presented a major bleeding. The characteristics of the patients from the POP-A-RIX and PROPICE studies and the pooled population are presented in Table 1 .
Study outcomes
Safety and efficacy data. The primary outcome was major bleeding (on treatment bleeding, from the first fondaparinux dose up to 3 days after the last dose). Major bleeding was defined as bleeding that was fatal, occurred in a critical organ (e.g. retroperitoneal, intracranial, intraocular and intraspinal bleeding), required reoperation, or warranted treatment cessation or clinically overt bleeding with a fall in the haemoglobin level of at least 2 g dl -1 or that required transfusion of two or more units of whole blood or packed cells. The efficacy outcome had to be documented objectively and was defined as the composite of symptomatic deep-vein thrombosis (DVT) and pulmonary embolism (PE). Finally, mortality was defined as all-cause mortality. An independent expert adjudication committee ascertained 64 major bleedings, nine VTE events and 11 deaths. Details of the outcome events are summarised in Table 2 .
Follow-up. Events were recorded during hospitalisation in the POP-A-RIX study and until last visit (day 45) in the PROPICE study. To compare our results with data of randomized control trials [2] , observed outcomes up to day 11 are presented.
Data analysis
Time-to-event analysis. The analysis was limited to the primary outcome, major bleeding and to consideration of the first event in the case of multiple events. There were too few VTE and death events to perform a time-to-event analysis for these events.
The time-to-major bleeding after the end of surgery was modelled using a parametric survival analysis (see [11] for an introduction to the process).
The relationship between the predictors X of the event, major bleeding, was evaluated using a model of the form:
Here, β are parameters and may be any real number. Negative values indicate a reduced hazard and positive values an increased hazard of major bleeding.
We first performed a proportional hazard analysis with non-time-varying covariates. Potential predictors of major bleeding were: age, sex, total body weight (Wt), lean body weight (LBW) [12] , preoperative creatinine clearance estimated by the Cockcroft-Gault equation using, as body size descriptor, Wt (CrCl Wt ) or LBW (CrCl LBW ), type of surgery, timing of first administration of fondaparinux relative to the end of surgery, and individual predicted fondaparinux exposure markers (area under the plasma concentration-time curve to infinite time calculated for one dose, AUC inf , maximum plasma concentration obtained after first administration of fondaparinux, Cmax dose1 and maximum plasma concentration value during dosing that preceded the event, Cmax). The time course of fondaparinux modelled as a time-varying covariate was also tested as an exposure marker. Fondaparinux exposure markers were calculated using a pharmacokinetic model derived from the pooling of the two cohorts (see Supporting Information).
The hazard at time, t, of an event is given by:
The baseline hazard (h 0 ) was considered a function of time and had the general form:
Here we allow the predictors of the base hazard (X 2 ) to differ from the predictors associated with the covariates of interest (X). The base hazard was allowed to be a nonlinear function of the parameters.
The cumulative hazard of an event to time, t, is given by:
hz t ð Þdt function for cumulative hazard to time t ð Þ And the survival function of an event to time, t, is given by:
ð Þ link between survival and cumulative hazard ð Þ
Model selection and evaluation
The parameters were estimated using the extended least squares approach with the conditional Laplacian-like estimation method implemented in NONMEM (version 7.2.0, Globomax, Hanover, MD, USA). Models were selected based on a likelihood ratio test where a decrease in objective function (OF) of >3.84 units is significant at P < 0.05 (one degree of freedom, χ 2 distributed) and on the basis of the precision of parameter estimation. Covariates were included in the proportional hazard models with forward selection (P < 0.05). Once the final model was obtained, covariates were removed by backward selection if the increase in objective function was <6.6 points (P < 0.01). Nonparametric confidence intervals (CI) of the parameter values were derived from 1000 bootstraps.
Visual predictive checks were performed to evaluate the adequacy of the selected survivor functions. They were based on the predicted survivor functions by estimating the Kaplan-Meier nonparametric survivor function derived from simulated events. To compare the simulated Kaplan-Meier curves with the observed Kaplan-Meier estimate, R package mlxR (version 3.2.0) was used.
Time to event simulations
The final survivor function, S (t), was used to simulate the probability of avoiding major bleeding for different values of the selected predictive risk factors. To examine the effect of drug exposure from different dosing regimens on the hazard of bleeding, we simulated 1000 datasets, each containing 1393 patients randomly sampled with replacement from the 
where b is a random effect which has a mean of zero and log normal between subject variability of 34 (CV%). The probability of major bleeding up to day 11, which is given by the cumulative distribution function (F (t) = 1-S (t)), was simulated with two dosages of fondaparinux, 1.5 mg once daily, the dosage recommended for patients with a CrCl Wt between 20 and 50 ml min -1 and 2.5 mg once daily, the dosage recommended for patients with a CrCl Wt above 50 ml min -1 [6] . Day 11 was chosen for comparisons purposes with the period of bleeding assessment in the phase III trials of fondaparinux.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [13] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [14] .
Results
Time-to-event analysis for major bleeding
The Kaplan-Meier plot of the probability of avoiding a major bleeding is presented in Figure 1 . The observed rate of major bleeding up to day 11 was 5.2% (95%CI 3.9-6.6%). Fifty-three of the 64 major bleeding events occurred between day 3 and day 8 indicating that the hazard of bleeding was highest in the first days following surgery and then remained low thereafter (Figure 2) .
The baseline hazard (h 0 ) was best described by:
which included a parameter for a lag time. Parameter values of the baseline hazard are given Table 3 and the function is illustrated in Figure 2 . During the univariate analysis of the proportional hazard model, hz (t), male sex was the only significant physiological covariate related to an increased hazard of major bleeding (reduction of the OF by 5.45 points, see Supplementary Table S1 ). Both AUC inf and Cmax dose1 were significant exposure markers (reduction of the OF by 10.5 and 5.34 points respectively). Neither Cmax nor the use of fondaparinux exposure as a time varying covariate improved the fit of the model. AUC inf was found to be the best predictor for the rate of major bleeding and thus retained as the exposure marker of fondaparinux for the multivariate analysis. Leading to re-intervention 6 3 9
With ≥20 g l During the multivariate analysis, the influence of sex remained as a predictor of bleeding events when combined to AUC inf (reduction in OF by 19.6 points). The model was improved by adding weight as a predictor, either Wt or LBW (reduction of the OF by 26.4 and 25.3 points respectively). The hazard of major bleeding increased as weight decreased. The addition of timing of first administration of fondaparinux after surgery, creatinine clearance (CrCl Wt or CrCl LBW ), age or type of surgery did not sufficiently improve the objective function. The full hazard model is given by:
The final parameters estimates and 95% confidence intervals are shown in Table 3 . Compared to women, men had a 5-fold increase in the hazard of bleeding (hazard ratio = 5.05, 95%CI 2.14-11.9). A doubling in AUC inf from the mean value observed in the study (8.5 mg l À1 h) increased the hazard of bleeding by 2.5. A similar increase in the hazard of bleeding would require a 21 kg decrease in LBW.
The final parametric survivor function with covariates is given by: Figure 2 Hazard of major bleeding. Histograms represent the empirical distribution of the hazard of major bleeding. Solid line represents the parametric function for the baseline hazard h 0 (t) 
percentile values)
The hazard of major bleeding increased in men (hazard ratio = 5.05, 95%CI 2.14-11.9), increased as lean body weight decreased (hazard ratio = 1.04, 95%CI 1.00-1.09 per 1 kg decrease) and increased as AUC inf increased (hazard ratio = 1.12, 95%CI 1.06-1.19 per 1 mg l À1 h increase)
Figure 1
Kaplan-Meier plot of the percentage of patients without major bleeding vs. time after surgery in days. Solid lines represent the Kaplan-Meier estimate of the observed data and 95% confidence interval. The shaded area represents the 95% prediction interval of simulated Kaplan-Meier curves using the parametric survivor function with covariates (lean body weight, sex and area under the plasma concentration-vs.-time curve to infinite time)
This final model was used to simulate Kaplan-Meier curves. The visual predictive check indicates that the parametric survivor function with covariates was suitable to predict the observed data (Figure 1 ).
Time to event simulations
The effects of LBW, sex and AUCinf on the probability of avoiding major bleeding are illustrated in Figure 3 .
To examine the potential benefit of adjusting the dose of fondaparinux in patients with renal impairment, the probability of major bleeding for different dosing regimens were simulated (1000 datasets each containing 1393 patients). In patients with renal impairment (CrCl wt between 20 and 50 ml min -1 ), median drug exposure (AUC inf ) were calculated to be 42% (95% CI 35-49%) higher than in patients with a CrCl Wt above 50 ml min -1 . At day 11, the probability of major bleeding for the 2.5 mg once a day regimen was 4.2% (95% CI 4.0-4.4%) in patients with a CrCl Wt above 50 ml min -1 and 6.5% (95% CI 6.2-6.9%) in patients with renal impairment. The probability of bleeding in patients with renal impairment was reduced to 3.8% (3.7-4.0%) with an adjusted dose of 1.5 mg once a day. The probability of major bleeding in subgroups according to sex and renal function are shown Table 4 .
Other events
The observed rate of symptomatic venous thromboembolism up to day 11 was 0.7% (95% CI 0.2-1.3%). All events occurred before day 10 except for one distal DVT (day 23). The Figure 3 Time to event simulations. LBW, lean body weight (kg). AUC, area under the plasma concentration-vs.-time curve to infinite time (mg l À1 h). The probability of avoiding major bleeding with fondaparinux thromboprophylaxis was lower in men, decreased as weight decreased and decreased as exposure to fondaparinux increased Table 4 The probability of major bleeding up to day 11 for different dosing regimens was simulated. Bootstrap median and 95% confidence interval is shown CrCl Wt, creatinine clearance estimated by the Cockcroft-Gault equation using, as body size descriptor, total body weight observed rate of all cause death up to day 11 was 0.5% (95% CI 0.1-0.9%).
Discussion
To our knowledge this study is the first to investigate the time-course of major bleeding after orthopaedic surgery in a real-world setting. The number of exclusion criteria was limited and therefore the characteristics of the patients of this study differed from the highly selected patients of the randomized control trials with fondaparinux thromboprophylaxis [2] . Patients in our study were older (76 vs. 68 years), had a lower body weight (68 vs. 77 kg) and there was higher proportion of patients with a CrCl wt <50 ml min -1 (47% vs. 17%) compared to patients included in the phase III trials with fondaparinux. Thus, patients were frailer, which could explain the higher rate of major bleeding by day 11 (5.2% vs. 2.7%). As previously suggested in randomized control trials of prolonged thromboprophylaxis, the majority of bleeding events occurred in the first days following surgery [15, 16] . The likelihood of a major bleeding progressively decreased after day 5 and remained low after day 11 ( Figure 2 ). This finding of the time course of the likelihood of a bleeding event is also consistent with the results of perioperative anticoagulation bridging studies that found an increase in major bleeding in patients with perioperative administration of therapeutic doses of heparin compared to patients who were not bridged and resumed an optimal level of anticoagulant therapy approximately 1 week after surgery [17] . In this study, patient characteristics varied from normal to extreme values, two dosages of fondaparinux were administered and anti-Xa activities were measured in every patient. We were therefore able to identify independent clinical and biological predictors of bleeding, which were male sex, lower body weight and increased AUC inf .
The relationship between increase exposure and bleeding events is consistent with the results of the phase II study of fondaparinux that showed an increased risk of major bleeding with increasing doses [18] . Although patients with renal impairment have increased fondaparinux exposure compared to patients with normal renal function [7] , we did not find that a decrease in creatinine clearance was an independent risk factor for bleeding in our multivariate analysis. A probable explanation is that the effect on bleeding of a decrease in glomerular filtration is already examined by the increase in the exposure marker. Similar findings have been reported with enoxaparin and apixaban [19, 20] . The increase hazard of bleeding in men and patients with lower body weight were previously demonstrated [3, 4] . Compared to women, the observed rate of major bleeding was increased in men by 1.8 in our study, by 1.3 in the phase III trials of fondaparinux and by 1.6 in a retrospective database study coming from US acute-care hospitals [3, 4] . Of note, the increase of bleeding was more important in one of the two cohorts that constituted our study, the PROPICE study, which only included patients with moderate to severe renal impairment [9] . In this latter study men had a 3.6-fold increase in major bleeding compared to women. To our knowledge, there is no biological reason for the increased hazard of bleeding in men. Male sex could be a confounding variable of a decrease in health status. In our multivariate analysis, the 95%CI of the 5-fold increase in hazard of bleeding in men (2.1-12) indicates a poor estimation of the magnitude of the effect. Therefore, great care should be taken when interpreting the magnitude of this hazard ratio. In our study, we chose LBW over Wt as body size descriptor for the following reasons. First, orthopaedic patients are often elderly. Low LBW is frequent in elderly patients and sarcopenia is a marker for frailty and poor outcomes [21] . Second, LBW is a useful dosing scalar that is transportable across all body compositions [22] . Timing of the first administration of an anticoagulant is important to consider when assessing major bleeding. In the phase III trials of fondaparinux, there was a significant relationship between the incidence of major bleeding and the timing of the first administration of fondaparinux [2] . In our study, 96% of the patients had their first dose given after the recommended timing for initiating therapy (at least 6 h following skin closure). This could explain why we did not show a relationship between bleeding and timing of first administration and supports the findings indicating to delay the administration of fondaparinux [23, 24] .
Only nine symptomatic VTE events were observed, suggesting that fondaparinux is a very effective agent for thromboprophylaxis in orthopaedic surgery. However, if major bleeding is considered as equivalent to symptomatic VTE in its disutility [1] , the number of major bleeding events observed in this study (64 events) raises the question of the appropriateness of the dosage administered.
At the time of the completion of the POP-A-RIX study [7] , no dose adjustment of fondaparinux was recommended in special populations. In September 2007, regulatory authorities recommended that the dose should be reduced to 1.5 mg once daily in patients with creatinine clearance in the range of 20-50 ml min -1 [6] . No dosage reduction was required for patients with a creatinine clearance >50 ml min -1 .
These recommendations were based on pharmacokinetic simulations that showed that a once-daily use of 1.5 mg fondaparinux in patients with moderate renal impairment yielded drug exposure comparable to that in patients with normal renal function at 2.5 mg once daily [5] . Simulations based on our pharmacodynamic model indicate that a reduced dosage in renal impaired patients could be effective to reduce the risk of bleeding (Table 4) . Our data support the dose adjustment rules recommended by regulatory authorities [6] .
Our study has a number of limitations. First, prolonged prophylaxis with fondaparinux was not administered to all the patients in the study. At the time of the POP-A-RIX trial, postdischarge prophylaxis with fondaparinux was not available and prophylaxis with fondaparinux beyond day 11 in the PROPICE trial was left at the discretion of the practitioner. Thus, survival estimates at the end of the study should be interpreted with caution, as shown by the width of the confidence intervals. Second, we postulated that dropouts occurred at random -i.e. that they were considered to have survival prospects similar to the participants who continued to be followed [11] . Although this is a strong assumption, our visual predictive check showed good agreement with the observed data and did not suggest the need to consider including a dropout model [25] . Third, certain risk factors for major bleeding such as concomitant use of antiplatelet agents, or surgical factors other than the type of surgery were not collected and their contribution to our models can therefore not be assessed [1] . Finally, this study cannot exclude whether a reduce dose of fondaparinux in renal impaired patients would increase the incidence or severity of venous thrombosis. However, only three symptomatic VTE events, all distal DVT, were observed in the 436 renal impaired patients treated with the reduced dose of fondaparinux 1.5 mg once daily [9] . This low rate of symptomatic VTE is consistent with that reported in patients receiving 2.5 mg once daily in phase III studies in major orthopaedic surgery [2] . It appears that fondaparinux 1.5 mg is a valuable thromboprophylactic option in orthopaedic patients with moderate renal impairment.
In conclusion, our results indicate that the hazard of major bleeding with fondaparinux thromboprophylaxis is highest in the first days following orthopaedic surgery. The hazard is increased in men, frail patients as assessed by low LBW and elevated drug exposure. To reduce the risk of major bleeding in patients with moderate renal impairment, this study supports the use of lower dose of fondaparinux 1.5 mg once daily.
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